Full Text
Comparing Modeling Approaches In Cost-Effectiveness Analysis Using Secondary Survival Data- A Study of Nivolumab Versus Everolimus In The Treatment of Metastatic Renal Cell Carcinoma

Abstract

Authors

S. Grewal

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×